The development of evidence-based clinical practice guidelines is a cornerstone of modern nephrology to facilitate shared decision-making, yet the creation of a guideline represents only the initial phase of the mission to improve outcomes for people living with kidney disease. The true impact of the rigorous, scientific process of Kidney Disease: Improving Global Outcomes (KDIGO) guideline development is realized only when recommendations are effectively disseminated, understood by healthcare professionals and patients, and implemented in clinical settings throughout the world. This manuscript outlines the comprehensive strategy employed by KDIGO to bridge the gap between global guidance and local practice. We review the core mission of KDIGO, the philosophy of "global guidance, local implementation," and the robust suite of educational tools, summits, and digital initiatives designed to disseminate the key messages from the guidelines and educate healthcare professionals to implement the guidelines in order to optimize patient outcomes worldwide.

New evidence relevant to the management of kidney disease is constantly being generated, underscoring the need for timely, rigorous, and trustworthy clinical practice guidelines that translate evidence into improved patient outcomes. The accelerating pace of innovation presents a challenge as well as an opportunity for rapid and seamless translation. This paper extends the work of earlier papers in the methodology series by describing the methods that Kidney Disease: Improving Global Outcomes (KDIGO) uses to prioritize topics and update existing guidelines and recommendations. Finally, we examine a living guideline framework, balancing the promise of more agile, up-to-date recommendations with the practical and methodological challenges inherent to continuous evidence integration.

Lupus nephritis flares are occasionally preceded by a rise in serologic activity. To date, watchful waiting is the suggested approach for patients with such a serologic reactivation. Yap et al. performed a randomized trial testing a pre-emptive increase in immunosuppression versus watchful monitoring in patients with stable lupus nephritis who had a rise in their anti-double-stranded DNA antibodies. We discuss their results in the context of the current landscape and expanding therapeutic options for the management of lupus nephritis.

Hierarchical composite kidney outcomes analyzed using win statistics prioritize important events while avoiding some limitations of traditional composite end points. Liu et al. apply this approach to 4 large hypertension trials. Their analysis illustrates how hierarchical comparisons behave when major kidney events are uncommon and most comparisons are resolved by lower-tier outcomes, in this case estimated glomerular filtration rate slope. In these settings, the win statistic largely reflects kidney function trajectories, making interpretation dependent on how slope is measured and defined.

Diabetic kidney disease remains a major clinical challenge despite advances in renoprotective therapies. In this issue of Kidney International, Qi et al. report that selective modulation of the vascular endothelial growth factor (VEGF) system differentially affects diabetic kidney disease progression across multiple advanced diabetic models. Whereas VEGF-A or VEGF receptor 2 inhibition exacerbated albuminuria, targeted VEGF receptor 1 blockade consistently conferred renoprotection, including in established disease. These findings clarify prior conflicting data and identify VEGF receptor 1 inhibition as a therapeutic strategy for diabetic kidney disease.